RESUMO
The association of ifosfamide with cisplatin and 5-fluorouracil for the management of advanced squamous cell carcinoma of the head and neck was assessed in this trial. Ifosfamide was given initially to 12 patients in combination with standard fixed doses of cisplatin and 5-fluorouracil, at 1,000 mg/m2 daily on days 2, 3, and 4. Two patients died of neutropenia and severe infection, and the authors recruited seven more patients who were treated with a lower dose of ifosfamide, 800 mg/m2 daily on days 2, 3, and 4. One of the seven patients died of neutropenia and severe infection. Three complete remission were observed in 18 patients evaluable for efficacy. The study was closed early because of the severe toxicity profile demonstrated by this scheme and because of no clear advantage in efficacy versus cisplatin plus 5-fluorouracil combinations.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma de Células Escamosas/tratamento farmacológico , Neoplasias de Cabeça e Pescoço/tratamento farmacológico , Adulto , Idoso , Cisplatino/administração & dosagem , Fluoruracila/administração & dosagem , Humanos , Ifosfamida/administração & dosagem , Masculino , Pessoa de Meia-Idade , Indução de Remissão , Análise de SobrevidaRESUMO
A case of microangiopathic hemolytic anemia associated to metastatic breast cancer, in remission with chemotherapy, is presented. We review the etiopathogenetic mechanism of its association and focus on the priority of neoplasia therapy when disseminated intravascular coagulation is not present.
Assuntos
Adenocarcinoma/complicações , Anemia Hemolítica/etiologia , Neoplasias da Mama/complicações , Adenocarcinoma/terapia , Adulto , Anemia Hemolítica/diagnóstico , Neoplasias Ósseas/secundário , Neoplasias da Mama/terapia , Terapia Combinada , Feminino , Humanos , Fatores de TempoRESUMO
Thirty-four patients with locally advanced or metastatic esophageal cancer were treated with cisplatin 35 mg/m2/day x 3 days in bolus, plus bleomycin 15 mg/day x 3 days, as an 18 h infusion, every 21-28 days. Twenty-nine are evaluable for response. Objective response was seen in 15 (52%, 95% confidence limits 35-69%) patients. Toxicity was mild. Twelve patients with locoregional disease were treated with this combination followed by radiotherapy and three of them are alive without disease at 18, 22 and 36 months. This combination warrants further study in the setting of combined treatment.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias Esofágicas/tratamento farmacológico , Idoso , Bleomicina/administração & dosagem , Cisplatino/administração & dosagem , Terapia Combinada , Neoplasias Esofágicas/radioterapia , Feminino , Humanos , Masculino , Metástase Neoplásica , PrognósticoAssuntos
Antígeno Carcinoembrionário/análise , Carcinoma/sangue , Neoplasias Colorretais/sangue , Recidiva Local de Neoplasia/sangue , Carcinoma/cirurgia , Neoplasias Colorretais/cirurgia , Feminino , Seguimentos , Humanos , Masculino , Metástase Neoplásica/sangue , Metástase Neoplásica/cirurgia , Recidiva Local de Neoplasia/cirurgia , Reoperação , Fatores de TempoRESUMO
Propósito: Descripción de las características clínicas de la hipersensibilidad al Carboplatino (CBDCA).Material y métodos: Presentamos cuatro casos de hipersensibilidad al CBDCA recogidos a lo largo de 14 meses entre 143 pacientes tratados con esta medicación. Resultados: Todas habían recibido tratamiento previo con CBDCA sin problemas y la reacción apareció tras uno o más ciclos. Todas presentaron ansiedad, tres prurito, una exantema, otra eritema, una tos, otra disnea, otra hipotensión y otra dolor torácico. En dos de ellas inicialmente la reacción se achacó al paclitaxel. Conclusión: Una reacción alérgica al CBDCA puede comprometer la vida del paciente por lo que es importante conocer los signos y síntomas de la misma para tratarla y evitar reexposiciones graves (AU)